Navigation Links
Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
Date:5/20/2008

equired colonoscopy alone, and those with treatable Stage II (Dukes Stage B) cancer (n=2) were diagnosed an average of 21.8 months earlier than they would have been with a study-required colonoscopy alone. Detection of advanced adenomas in the FIT cohort (n=60; non-FIT n=54) occurred 18.4 months earlier than would have occurred during the study-required colonoscopy.

Overall, the interim report showed that interval FIT testing under this study program detected 86 percent (12 of 14) of colorectal cancers and 63 percent (60 of 96) of advanced adenomas greater than 10 mm.

Colorectal cancer is the second leading cause of cancer death in the United States(1), but when found early and treated, the five-year relative survival rate for colon cancer is 90 percent.(2) Currently, less than 40 percent of colorectal cancers are found early.(3) The new data presented today at DDW suggest that annual colorectal screening with FIT tests may help increase early detection.

"Our interim report indicates that undertaking annual FIT testing in high-risk groups -- between planned surveillance colonoscopies -- is valuable because it reduces delays in the diagnosis and treatment of colorectal cancer and advanced adenomas," said primary investigator Graeme P. Young, MD, FRACP, Professor of Gastroenterology and Academic Head of GI Services, Director, Flinders Centre for Innovation in Cancer of South Australia. "For the medical community dedicated to preventing and treating this major disease, we now have evidence that annual screening of high-risk patients with a convenient, take-at-home test can catch not only colorectal cancer earlier but advanced adenomas as well, given the notable CSP study program sensitivity of 63 percent."

American Cancer Society (ACS) guidelines recommend colonoscopy every five years for patients with a family history of colorectal cancer and for patients with a personal history of colorectal cancer who have had a normal 3-year colonoscopy,
'/>"/>

SOURCE Quest Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
7. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
10. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Outcome of Intrauterine Insemination and In Vitro Fertilization Procedures , ... Inc. (OTC Bulletin Board: CDXP) announced today that it has ... regarding a license to develop and market Cordex,s drug candidate, ... drug candidate designed for in vitro (outside of ...
... , SOMERSET, N.J., June 19 , , Dear ... share with you important developments taking place at this critical juncture in ... the first of many as your president. , , Like ... of this company. I want you to know I am fully committed ...
Cached Medicine Technology:Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 2Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 3Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 4Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 5Alfacell Provides Shareholder Update 2Alfacell Provides Shareholder Update 3Alfacell Provides Shareholder Update 4Alfacell Provides Shareholder Update 5Alfacell Provides Shareholder Update 6
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... 26, 2010 Global scientific, technical, medical and scholarly ... clinical decision support product, Essential Evidence Plus (EE+), is ... move can now easily find answers to challenging point-of-care ... other Smartphones. EE+ is accessible through ...
... The National Institute of Diabetes and Digestive and Kidney ... has awarded Albert Einstein College of Medicine of Yeshiva ... of its Diabetes Research and Training Center (DRTC). The ... equipment and additional pilot and feasibility studies through the ...
... from biologic meds, study finds , TUESDAY, May 25 ... less likely to be used by American rheumatoid arthritis ... with medical co-payments, a new study reveals. , Biologics, ... treat rheumatoid arthritis when more conventional treatments don,t work. ...
... spent less time in the hospital when treated using ... medical care focusing on increasing muscle motion in ... Kari Hortos, a Michigan State University professor in the ... one of seven site investigators as part of the ...
... ... Shore. , ... May 25, 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. (BCBSMA) and ... Alternative Quality Contract (AQC). The agreement marks the first North Shore physician group ...
... ... Costs. Two of Southern California,s leading physician-governed medical groups, along with Anthem Blue Cross, ... rewards providers for improving patient outcomes, while slowing cost growth. , , ... (PRWEB) May 25, 2010 ...
Cached Medicine News:Health News:Mobile access now available for Essential Evidence Plus 2Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Out-of-Pocket Costs Limit Access to Arthritis Drugs 2Health News:Hands-on osteopathic treatment cuts hospital stays for pneumonia patients 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 2Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 3Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 4
For the quantitative in vitro determination of Urea in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
Medicine Products: